Aetiology, clinical presentation and treatment of testicular cancer
CPD Previous     Next

Aetiology, clinical presentation and treatment of testicular cancer

Clare Akers Clinical nurse practitioner, University College Hospital, University College London Hospitals NHS Foundation Trust, London, England

Testicular cancer is a highly treatable and curable malignancy. It typically affects men aged 15-35 years and is the most common malignancy in this age group. Nurses have an important role in assisting patients to cope with the diagnosis and understand the treatment options. It is also important for nurses to provide psychological support, because testicular cancer can have a significant effect on a man’s fertility, sexuality and body image. This article examines the epidemiology and aetiology of the disease, together with its clinical presentation and treatment options. It emphasises the importance of early detection of testicular cancer to improve its prognosis, through awareness of the signs and symptoms of the disease and undertaking regular testicular self-examination.

Nursing Standard. 32, 28, 50-61. doi: 10.7748/ns.2018.e11001


Peer review

This article has been subject to external double-blind peer review and checked for plagiarism using automated software

Conflict of interest

None declared


Prepare for revalidation: read this CPD article, answer the questionnaire and write a reflective account:

To write a CPD article

Please email Guidelines on writing for publication are available at:

Received: 06 September 2017

Accepted: 15 February 2018

Want to read more?

Subscribe for unlimited access

Try 1 month’s access for just £1 and get:

Your subscription package includes:
  • Full access to and the Nursing Standard app
  • The monthly digital edition
  • RCNi Portfolio and interactive CPD quizzes
  • RCNi Learning with 200+ evidence-based modules
  • 10 articles a month from any other RCNi journal
RCN student member? Try Nursing Standard Student
Already subscribed? Log in

Alternatively, you can purchase access to this article for the next seven days. Buy now